期刊文献+

Ki-67表达对髓母细胞瘤患者预后的影响

Influence of Ki-67 on the prognosis of patients with medulloblastoma
收藏 分享 导出
摘要 目的探讨Ki-67对髓母细胞瘤患者预后的影响。方法回顾性分析2009年1月至2018年1月郑州大学第一附属医院收治的经术后病理结果证实为髓母细胞瘤的患者109例,采用Kaplan-Meier法计算总生存期和无进展生存期的生存率,各因素生存率的比较采用Log-rank检验,应用Cox比例风险模型评估法行多因素分析。结果与Ki-67≤50%的髓母细胞瘤患者相比,Ki-67>50%的髓母细胞瘤患者的无进展生存期(P=0.006)及总生存期(P=0.017)均缩短;Ki-67是影响髓母细胞瘤患者预后的独立危险因素。结论随着Ki-67的升高,髓母细胞瘤患者的预后越差,Ki-67是髓母细胞瘤患者潜在的预后标志物。 Objective To investigate the effects of Ki-67 on the prognosis of patients with medulloblastoma. Methods A total of 109 patients with medulloblastoma confirmed by postoperative pathology in the First Affiliated Hospital of Zhengzhou University from January 2009 to January 2018 were enrolled in the study. Kaplan-Meier method was used to calculate the survival rates of the overall survival (OS) and progression-free survival (PFS). The survival rates of these factors were compared by Log-rank test. The Cox proportional hazard model was evaluated by multivariate analysis. Results The progression-free survival (P=0.006) and total survival (P=0.017) of medulloblastoma patients with Ki-67>50% were shorter than those of medulloblastoma patients with Ki-67< 50%. Ki-67 was an independent risk factor influencing prognosis of patients with medulloblastoma. Conclusions With the increase in Ki-67, prognosis of patients with medulloblastoma get worse. Ki-67 is a potential prognostic marker for patients with medulloblastoma.
作者 李克 耿俊杰 张振宇 刘献志 张智峰 Li Ke;Geng Junjie;Zhang Zhenyu;Liu Xianzhi;Zhang Zhifeng(Department of Neurosurgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China)
出处 《中国实用医刊》 2019年第11期1-3,共3页 Chinese Journal of Practical Medicine
基金 国家自然科学基金项目(81702465).
关键词 KI-67 髓母细胞瘤 预后 生存期 Ki-67 Medulloblastoma Prognosis Survival
作者简介 通信作者:张智峰,Email:zzfh72@sina.com.
  • 相关文献

参考文献6

二级参考文献47

  • 1李宝江,朱志华,王军业,侯景辉,赵进明,张蓬原,姚广裕,王曦,龙浩,杨名添,戎铁.Ki67、P53、VEGF和C-erbB-2在乳腺癌组织中表达的相关性研究及其临床意义[J].癌症:英文版,2004,23(10):1176-1179. 被引量:106
  • 2Omuro A M,Faivre S,Raymond E.Lessons learned in the development of targeted therapy for malignant gliomas[J].Mol Cancer Ther,2007,6:1909-1919. 被引量:1
  • 3Villar E,Salazar R,Pérez-Garcia J,et al.Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors[J].Endocr Relat Cancer,2007,14:221-232. 被引量:1
  • 4Faria M H,Goncalves B P,do Patrocínio R M,et al.Expression of Ki-67,topoisomerase IIalpha and c-MYC in astrocytic tumors:correlation with the histopathological grade and proliferative status[J].Neuropathology,2006,26:519-527. 被引量:1
  • 5Lindboe C F,Torp S H.Comparison of Ki-67 equivalent antibodies[J].J Clin Pathol,2002,55:467-471. 被引量:1
  • 6Johannessen A L,Torp S H.The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas[J].Pathol Oncol Res,2006,12:143-147. 被引量:1
  • 7Bowers D C,Gargan L,Kapur P,et al.Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents[J].J Clin Oncol,2003,21:2968-2973. 被引量:1
  • 8Shaffrey M E,Farace E,Schiff D,et al.The Ki-67 labeling index as a prognostic factor in Grade Ⅱ oligoastrocytomas[J].J Neurosurg,2005,102:1033-1039. 被引量:1
  • 9Brell M,Tortosa A,Verger E,et al.Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas[J].Clin Cancer Res,2005,11:5167-5174. 被引量:1
  • 10Nakasu S,Fukami T,Baba K,et al.Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas[J].J Neurooncol,2004,70:333-340. 被引量:1

共引文献10

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈